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Introduction: The combination of paclitaxel/carboplatin (PC) and
bevacizumab (B) was previously shown to extend overall survival
(OS) in patients with advanced nonsquamous non-small cell lung
cancer (NSCLC). An analysis of survival and safety outcomes based
on histology is presented here.
Methods: Patients with cytologically or histologically confirmed
metastatic NSCLC were treated with PC  B (PCB) or PC. Median
OS for all patients was determined using Kaplan-Meier methodol-
ogy. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
obtained using an unstratified Cox proportional hazards model.
Histology-by-treatment interaction was tested with an unstratified
multivariate Cox regression model.
Results: A total of 444 patients were randomized to PC, and 434
patients were randomized to PCB (the intent-to-treat population).
Median OS times were 10.3 and 12.3 months for PC and PCB,
respectively, with an HR for PCB of 0.80 (95% CI: 0.69–0.93). A
total of 68.8% of patients had adenocarcinoma histology; 18.9% had
“not otherwise specified”; 5.5% had large cell undifferentiated;
2.6% had bronchoalveolar carcinoma; and 3.9% “other.” For ade-
nocarcinoma, median OS was 10.3 months for PC treatment (n 
302) and 14.2 months for PCB (n  300), HR 0.69 (95%CI:
0.58–0.83). Sample sizes for other specific histologic subtypes were
too small for meaningful comparisons. Safety profiles among his-
tologies were consistent with the overall safety profile, and there
were no unexpected adverse event trends.
Conclusions: Addition of B to PC is associated with increased
survival in previously untreated patients with nonsquamous
NSCLC. Adenocarcinoma was associated with an increased survival
benefit of PCB treatment. Data for other histologies are inconclu-
sive, primarily because of small patient sample sizes and large CIs.
Key Words: Non-small cell lung cancer, Bevacizumab, Nonsqua-
mous, Histology, Adenocarcinoma.
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It is estimated that 215,020 cases of lung cancer were newlydiagnosed in 2008 and that more than 160,000 men and
women died of the disease.1 Non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers.2
The recombinant, humanized monoclonal antibody bevaci-
zumab (B; Avastin; Genentech, South San Francisco, CA) in
combination with paclitaxel (P) and carboplatin (C) is ap-
proved by Food and Drug Administration for first-line treat-
ment of patients with unresectable, locally advanced, recur-
rent or metastatic nonsquamous NSCLC.3–6 B binds to a
vascular endothelial growth factor, an essential endothelial
cell mitogen and survival factor, and a key factor in tumor-
associated angiogenesis. In a phase III randomized control
trial conducted by Eastern Cooperative Oncology Group
(ECOG), the median overall survival (OS) for patients with
NSCLC receiving PC  B (PCB) was 12.3 months, com-
pared with 10.3 months for patients who received paclitaxel/
carboplatin (PC) alone.3 The median progression-free sur-
vival (PFS) time was 6.2 months for patients who received
PCB, compared with 4.5 months for patients who received
PC alone.
The diagnosis of NSCLC comprises a number of his-
tologies based primarily on pathologic or cytologic review of
surgical specimens. The most common histologies are ade-
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nocarcinoma (the most frequently encountered histology in
NSCLC), squamous cell, and large cell carcinomas.2 Bron-
choalveolar carcinoma is a subtype of adenocarcinoma. In
addition, NSCLC can be classified as “not otherwise speci-
fied” (NOS) or “other,” which includes rare subtypes such as
spindle and giant cell carcinomas or carcinosarcomas. The
contribution of histology to the natural history or treatment
outcomes in NSCLC is not fully characterized. Most prior
studies evaluating therapeutics for treatment of NSCLC have
not documented differences in outcomes (survival or toxicity)
based on tumor histology.7 A phase III study comparing four
different regimens conducted in the 1980s8 and a more recent
trial comparing docetaxel/gemcitabine with docetaxel/cispla-
tin9 documented different response rates but no differences in
survival rates, based on different histologies.
Recently, however, Scagliotti et al10 compared tumor
histologies and effects on survival outcomes for patients
treated with cisplatin/pemetrexed or cisplatin/gemcitabine.
Patients treated with cisplatin/pemetrexed had more favorable
survival outcomes if they had tumors of adenocarcinoma
histology (n 847; 12.6 versus 10.9 months, respectively) or
large-cell carcinoma histology (n  153; 10.4 versus 6.7
months, respectively), compared with patients receiving cis-
platin/gemcitabine. Conversely, the cisplatin/gemcitabine
combination showed greater efficacy against squamous his-
tologies than cisplatin/pemetrexed.10
The correlation of tumor histology with B treatment
outcomes has not been analyzed previously, although patients
with squamous lung cancer have historically been excluded
from pivotal trials of B because of a safety concern, namely
pulmonary hemorrhage.3–5 This report presents the results of
a retrospective analysis of NSCLC histology in first-line
patients from the E4599 phase III trial of PC versus PCB and
assesses the survival and toxicity outcomes based on different
histology subtypes.
METHODS
Patient Population and Histologies
Patients in the phase III E4599 study3 had histologically or
cytologically confirmed, newly diagnosed stage IIIB (malignant
pleural effusion, not recurrent) or stage IV (recurrent or not
recurrent) nonsquamous NSCLC. Histology was confirmed at
baseline, including adenocarcinoma, bronchoalveolar, large cell
undifferentiated, NOS, and other. Mixed tumors were catego-
rized by the predominant cell type unless small cell histologic
elements were present, in which case the patient was ineligible.
Cytologic or histologic elements were established on metastatic
tumor aspirates or biopsy (centralized review of histology and
pathology review were not performed, and core biopsies were
not required for histologic categorization). Other eligibility cri-
teria for E4599 have been described by Sandler et al,3 including
ECOG performance status of 0 or 1; adequate bone marrow,
hepatic, and renal function; and informed consent. Exclusion
criteria included history of major hemoptysis, brain metastasis,
recent history of bleeding or thrombotic events, uncontrolled
hypertension, and ongoing therapeutic anticoagulation. Patients
with either measurable or nonmeasurable disease were eligible.
Investigations in patients were performed after approval by a
local Human Investigations Committee and in accordance with
an assurance filed with and approved by the Department of
Health and Human Services.
The E4599 intent-to-treat patient population included
some patients in the National Cancer Institute (NCI) extended
participation project, which was designed to extend clinical
trial privileges to qualified oncologists who were not the
members of an NCI cooperative group.11
Study Design
The study design for E4599 has been described.3 Ran-
domized patients (N 878) were stratified by the presence of
measurable disease, prior radiotherapy, percentage weight
loss (5%, 5%), and disease stage (IIIB not recurrent, IV
not recurrent, and IV recurrent). Patients were randomly
assigned to one of two treatment arms: (1) treatment with P
(200 mg/m2, day 1), C (area under the curve  6 mg/ml, day
1) and B (15 mg/kg, day 1), or (2) treatment with PC alone.3
Treatment cycles were repeated every 3 weeks, and tumor
assessments were performed every 6 weeks. Patients in the
PC cohort stopped chemotherapy after six cycles. Patients on
PCB stopped chemotherapy after six cycles and continued on
B until disease progression. All tumor responses were deter-
mined using RECIST, and toxicity was graded using the NCI
Common Terminology Criteria, version 2.0 (Cancer Therapy
evaluation Program, April 30, 1999). The primary endpoint
of the study was OS.
Statistical Methods
Baseline demographics and patient characteristics are
provided for all enrolled patients and are summarized de-
scriptively by histology subtypes. Categorical data are sum-
marized by number (n) and percent, and continuous data are
summarized by medians with ranges. Fisher’s exact test was
used to test for differences in categorical data.
Efficacy analyses were performed for all randomized
patients, the intent-to-treat population. The effects of histol-
ogy type on duration of survival and PFS were prespecified in
the Statistical Analysis Plan of the trial and were examined in
exploratory analyses. OS was defined as the time from ran-
domization to death from any cause; PFS was defined as time
from randomization to disease progression or death from any
cause. An unstratified Cox proportional hazards model was
used to estimate the hazard ratios (HRs) and 95% confidence
intervals (CIs) for OS and PFS by histology subtype. One-
and 2-year OS rates were estimated for the two treatment
arms based on Kaplan-Meier methodology. An unstratified
multivariate Cox regression model adjusted for relevant prog-
nostic factors (sex, presence of measurable disease, prior
radiotherapy, percent weight loss [5%], and disease stage)
was used to evaluate the histology-by-treatment interaction.
Ad hoc statistical power was calculated for the subset anal-
ysis. For analysis of OS, patients who withdrew from the
study or had missing data were censored at the date they were
last known to be alive. For analysis of PFS, patients were
censored at the time of last tumor assessment.
In the previous report on the E4599 data by Sandler et
al,3 analyses were based on the evaluable patient population
(n  850), not the intent-to-treat population (n  878) as
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reported here, thereby leading to slightly different point
estimates. Sensitivity analysis for OS was performed for the
protocol eligible patients in each histology subgroup. Extent
of exposure data is presented for the 859 treated patients who
were not in the NCI expanded participation project, which did
not collect information on extent of exposure.
The incidence of grade 3 to 5 toxicities was assessed by
histology subtype for patients in both study treatment arms.
This analysis was exploratory and not prespecified in the
trial’s statistical analysis plan. Results (n and percent) are
provided descriptively.
RESULTS
Baseline Patient Characteristics by Histology
A total of 878 intent-to-treat patients were randomized
into the PC or PCB treatment arms, with 875 providing
categorizable histology data. The predominant tumor histol-
ogy was adenocarcinoma (68.8%), 18.9% of patients had
tumors of NOS histology, 5.5% had large cell undifferenti-
ated histology, 2.6% had bronchoalveolar (bronchoalveolar
carcinoma) histology, and 3.9% had tumors of “other” his-
tology (Table 1). Three patients (0.3%) in the intent-to-treat
population described in this report had squamous tumors.
Baseline demographics and patient characteristics for
the overall patient population and based on tumor histology
are shown in Table 1. Median age ranged from 61 to 68 years,
and there were very few patients younger than 40 years.
Gender, weight loss, and ECOG performance status were
comparable across the histology subtypes; breakdown ac-
cording to baseline disease stage varied among histology
subtypes (P  0.005) (Table 1). Demographic characteristics
were similar across the PC or PCB treatment cohorts within
each histology subgroup, except for sex, with a higher pro-
portion of males in the adenocarcinoma PC cohort (P 
0.04), compared with the PCB cohort and the overall patient
population (P  0.03) (data not shown).
Survival Outcomes
Results are presented for the intent-to-treat patient pop-
ulation (n  878). For patients with adenocarcinoma histol-
ogy (68.8% of patients), median OS was 10.3 months for
treatment with PC alone and 14.2 months for PCB, with an
HR of 0.69 (95% CI: 0.58–0.83) for PCB (Figure 1A). The
1-year survival rate for patients with adenocarcinoma was
0.565 (95% CI: 0.508–0.621) for PCB, and the 2-year sur-
TABLE 1. Baseline Demographics and Patient Characteristics for Randomized Patients, by Histology
Total
(N  878)a
Histology
Adenocarcinoma,
n  602 (68.8%)
Bronchoalveolar
Carcinoma,
n  23 (2.6%)
Large Cell
Undifferentiated,
n  48 (5.5%)
Not Otherwise
Specified,
n  165
(18.9%)
Squamous,
n  3
(0.3%)
Other,
n  34
(3.9%)
Median age, yr (range) 63.0 (27–88) 62.0 (27–85) 68.0 (38–79) 61.0 (35–78) 64.0 (35–88) 63.0 (59–68) 65.0 (47–79)
Sex, n (%)
Male 478 (54.4) 323 (53.7) 13 (56.5) 30 (62.5) 89 (53.9) 2 (66.7) 19 (55.9)
Female 400 (45.6) 279 (46.3) 10 (43.5) 18 (37.5) 76 (46.1) 1 (33.3) 15 (44.1)
Race, n (%)
White 753 (85.8) 513 (85.2) 20 (87.0) 41 (85.4) 149 (90.3) 2 (66.7) 26 (76.5)
Black 47 (5.4) 34 (5.6) 1 (4.3) 2 (4.2) 6 (3.6) 0 3 (8.8)
Other raceb 30 (3.4) 20 (3.3) 2 (8.7) 1 (2.1) 5 (3.0) 1 (33.3) 1 (2.9)
Otherc 48 (5.5) 35 (5.8) 0 (0.0) 4 (8.3) 5 (3.0) 0 (0.0) 4 (11.8)
ECOG performance status,
n (%)
0 346 (39.6) 233 (38.8) 9 (39.1) 22 (46.8) 69 (42.1) 1 (33.3) 12 (35.3)
1 528 (60.4) 368 (61.2) 14 (60.9) 25 (53.2) 95 (57.9) 2 (66.7) 22 (64.7)
Prior radiotherapy, n (%) 80 (9.1) 54 (9.0) 1 (4.3) 2 (4.2) 18 (11.0) 1 (33.3) 4 (11.8)
Disease stage, n (%)
IIIb, not recurrent 108 (12.3) 90 (15.0) 0 3 (6.3) 11 (6.7) 0 3 (8.8)
IV, not recurrent 669 (76.4) 437 (72.7) 18 (78.3) 43 (89.6) 140 (84.8) 2 (66.7) 28 (82.4)
IV, recurrent 99 (11.3) 74 (12.3) 5 (21.7) 2 (4.2) 14 (8.5) 1 (33.3) 3 (8.8)
Measurable disease, n (%) 800 (91.2) 537 (89.2) 21 (91.3) 46 (95.8) 158 (95.8) 3 (100.0) 33 (97.1)
Weight loss in previous 6
mo, n (%)
5% 624 (71.6) 436 (72.8) 12 (54.5) 32 (66.7) 117 (71.8) 2 (66.7) 23 (67.6)
5–10% 155 (17.8) 102 (17.0) 9 (40.9) 10 (20.8) 26 (16.0) 1 (33.3) 7 (20.6)
10% 92 (10.6) 61 (10.2) 1 (4.5) 6 (12.5) 20 (12.2) 0 4 (11.8)
a Histology data were missing for three patients. The denominator for all percentages presented is for number of patients with nonmissing values.
b Other Race includes: Hispanic, Asian, Native American, Indian (Asian), or Filipino.
c Other includes patient or institutional refusal to provide information, unknown, and other.
ECOG, Eastern Cooperative Oncology Group.
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vival rate was 0.271 (95% CI: 0.216–0.326) for PCB (Figure
1B). In this histology analysis, median PFS for patients with
adenocarcinoma was 5.0 months for PC alone compared with
6.6 months for PCB (HR  0.65, 95% CI: 0.54–0.78)
(Figure 1C). Sensitivity analysis was performed for evaluable
patients with adenocarcinoma; median OS was 10.3 months
for patients in the PC alone arm and 14.8 months for PCB,
with an HR of 0.68 (95% CI: 0.56–0.82).
For the NSCLC NOS subtype, the HR for OS associ-
ated with PCB treatment was 1.16 (95% CI: 0.84–1.61;
Figure 1A), whereas the HR for PCB-associated PFS was
0.78 (95% CI: 0.55–1.09; Figure 1C). When all nonadeno-
carcinoma histologies were pooled, the median OS was 10.2
months for PC (n  140) and 9.6 months for PCB (n  133),
HR  1.14 (95%CI: 0.88–1.47). The pooled nonadenocarci-
noma group is a heterogenous group of histologies; the
majority of patients have NOS histology, which is a poorly
characterized histology.
The addition of B to the PC seemed to result in a trend
toward PFS benefit for patients with NOS tumor histology,
but CIs were wide and results are not statistically significant
for NOS. A treatment benefit for PFS associated with PCB
combination therapy was noted across most other histology
subtypes, but the results were not statistically significant.
(Histology data were not available for one patient receiving
PCB and for two patients receiving PC.)
For PFS and OS, the point estimates for the interaction
effect adjusted by sex, presence of measurable disease, prior
All patients 878 444 4.8 434 6.4 0.66 (0.57 - 0.77)
Histological type
    Adenocarcinoma 602 302 5.0 300 6.6 0.65 (0.54 - 0.78)
    Large Cell Undifferentiated 48 30 4.3 18 8.5 0.35 (0.15 - 0.79)
    Squamous 3 2 7.1 1 22.4 0.00 (0.00 -  ) 
    Bronchoalveolar (BAC) 23 11 4.5 12 6.1 1.09 (0.43 - 2.79)
    NSCLC, NOS 165 86 4.7 79 5.7 0.78 (0.55 - 1.09)
    Other   34 11 6.0 23 6.6 0.54 (0.19 - 1.52)
0.2 0.5 1 2 5
Baseline Characteristic (95% CI)
Total
n
Hazard
Ratio Hazard Ratio
PC_________
     Median
 n  (months)
PCB_________
     Median
 n  (months)
C  Progression-Free Survival: Hazard Ratiosa and Forest Plotsb  
302
300
284
281
247
265
216
249
180
224
149
193
126
165
96
146
82
122
70
100
51
81
39
63
27
48
19
34
11
30
6
21
4
15
4
9
2
6
1
6
1
5
0
2
0
1
0
0
0
0
0
0
PC (n=302)
0.0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
Duration of Survival (months)
P
ro
po
rti
on
 S
ur
vi
vi
ng
PCB (n=300)
B  Duration of Survival for Adenocarcinoma, by Treatment 
12 months,  
 (95% CI)
0.565
(0.508, 0.621)
0.433 
(0.376, 0.490)
24 months,  
 (95% CI)
0.271
(0.216, 0.326)
0.168
(0.121, 0.216)
Patients
at risk:
PC
PCB
All patients 878 444 10.3 434 12.3 0.80 (0.69 - 0.93)
Histological type
    Adenocarcinoma 602 302 10.3 300 14.2 0.69 (0.58 - 0.83)
    Large Cell Undifferentiated 48 30 8.7 18 10.0 1.15 (0.60 - 2.24)
    Squamous 3 2 12.3 1 22.4 0.00 (0.00 -  )
    Bronchoalveolar (BAC) 23 11 17.7 12 10.0 1.48 (0.57 - 3.89)
    NSCLC, NOS 165 86 10.0 79 9.5 1.16 (0.84 - 1.61)
    Other   34 11 12.6 23 8.4 0.92 (0.43 - 1.98)
0.2 0.5 1 2 5
Baseline Characteristic (95% CI)
Total
n
Hazard
Ratio Hazard Ratio
PC_________
     Median
 n  (months)
PCB_________
     Median
 n  (months)
A  Overall Survival, by Histology Subtype: Hazard Ratiosa and Forest Plotsb 
FIGURE 1. Survival outcomes by
histology type. A, Median OS and
HR with forest plots are shown for
PC- or PCB-treated NSCLC patients
with different histology types. HRs
are from unstratified models. B,
Kaplan-Meier curves are shown for
OS of patients with adenocarci-
noma histology treated with PC or
PCB; 12- and 24-month survival
rates are indicated. C, Median PFS,
described as for OS in (A). NSCLC,
non-small cell lung cancer; NOS,
not otherwise specified; PC, pacli-
taxel/carboplatin; PCB, paclitaxel/
carboplatin  bevacizumab; OS,
overall survival; HR, hazard ratio;
PFS, progression-free survival.
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radiotherapy, percentage of weight loss (5%), and disease
stage suggest that there is no difference in the treatment
benefit for the histology subtypes. An analysis of OS treat-
ment effect adjusted by histology (P  0.009), gender (P 
0.0001), presence of measurable disease (P  0.9), prior
radiotherapy (P  0.3), percentage of weight loss (P 
0.0001), and disease stage (P  0.053) showed that the
benefit associated with PCB treatment remained; the adjusted
HR indicates an approximately 19% reduction in the hazard
of death among patients in the PCB arm compared with those
in the PC arm (data not shown). Except for adenocarcinoma,
the other histology subtypes included in this study were not
sufficiently powered for significance testing of PFS and OS;
for example, in the NSCLC NOS subgroup, for which 133
deaths were reported, the power to detect a 30% improvement
in survival is only 33%.
Exposure to Study Treatment
Extent of exposure to study treatment varied by histol-
ogy and treatment regimen (Table 2). (Nine patients in the
NCI expanded participation project, in which exposure data
were not routinely collected, were not included in the extent
of exposure analyses.) For patients receiving PC, median
number of treatment cycles (four to five cycles) and duration
of treatment (2.2–3 months) were comparable across all
histology subtypes. For patients with adenocarcinoma histol-
ogy receiving PCB, the median number of cycles was 8.0
(range: 1–47), and median duration of study treatment was
4.9 months (range: 0.03–33.54). For patients with NOS and
other histologies receiving PCB, the median number of cycles
were 6.0 and 5.5, respectively (range: 1–30; 1–32), and the
median durations of study treatment were 3.6 and 3.5 months,
respectively (range: 0.03–20.57; 0.02–22.24). Although no
patients in the PC treatment arm received more than six
cycles (per protocol), 43.5 to 57.4% of patients in the PCB
arm received more than 6 cycles, with 24.1% of adenocarci-
noma patients exposed to more than or equal to double that
number of cycles (data not shown).
Safety Outcomes
The safety profile across histologies was generally
consistent with that seen in the overall study population, with
no unexpected adverse event trends (Table 3). For the 868
safety evaluable patients in the study, the incidence of grade
3 hypertension, venous thromboembolic events, or protein-
uria seemed to be higher in adenocarcinoma patients treated
with PCB, compared with other histologies. However, com-
parative analysis is limited by the low total event numbers,
the low numbers of patients with nonadenocarcinoma histol-
ogies, and the fact that patients with adenocarcinoma re-
ceived longer study treatment with PCB. Although the inci-
dence of grade 3 to 5 bleeding events associated with B
treatment was higher in the PCB arms across all histologies,
patients with NSCLC NOS experienced a greater incidence of
grade 5 bleeding events (3 [3.8%] pulmonary hemorrhage
events) than patients with other histologies (Table 3).
Overall, there were 5 (1.7%) deaths among patients
with adenocarcinoma histology because of protocol treat-
ment. Patients with adenocarcinoma who were treated with
PCB were less likely to die as a result of disease (62.3%) than
patients with adenocarcinoma who received PC alone
(71.2%) or patients with tumors of other histologies (Table
4). Five patients (1.7%) with adenocarcinoma who were
treated with PCB died because of protocol treatment, versus
1 each for PC-treated patients with adenocarcinoma and for
PCB-treated patients with other histologies.
DISCUSSION
The addition of B to PC chemotherapy in previously
untreated patients with metastatic nonsquamous NSCLC is
associated with an increase in OS.3–5 This retrospective anal-
ysis for the E4599 study examined the efficacy and safety
outcomes based on tumor histology in patients treated with
PC or PCB regimens. Adenocarcinoma was the most frequent
histology in the study (68.8% of patients) and was associated
with a favorable median OS (14.2 months [HR  0.69]) in
patients who received PCB, the longest median survival
duration that has been reported in patients with NSCLC,
compared with patients who received PC alone (10.3
months). Median PFS time was also increased in adenocar-
cinoma patients treated with PCB (HR of 0.65, compared
with patients who received PC).
There seemed to be a consistent benefit associated with
B treatment on PFS across all histology subtypes and in the
overall population, but OS data for patients with the remain-
ing histology subtypes are largely inconclusive. Patients with
tumors of NOS histology, the second most frequent histology
TABLE 2. Exposure to Study Treatment for Treated Non-EPPa Patients, by Histology
Adenocarcinoma Histology
(n  592)
NSCLC NOS Histology
(n  160)
Other Histologiesb
(n  107)
PC (n  298) PCB (n  294) PC (n  84) PCB (n  76) PC (n  55) PCB (n  52)
No. of treatment cycles received
Mean (SE) 4.3 (0.1) 9.4 (0.4) 4.3 (0.2) 7.1 (0.7) 4.0 (0.3) 8.0 (1.0)
Median (range) 5.0 (1–6) 8.0 (1–47) 5.0 (1–6) 6.0 (1–30) 4.0 (1–6) 5.5 (1–32)
Duration of study treatment (mo),
median (range)
2.8 (0.03–13.6) 4.9 (0.03–33.54) 3.0 (0.03–12.75) 3.6 (0.03–20.57) 2.2 (0.03–4.63) 3.5 (0.02–22.24)
a Extent of exposure data was not collected for EPP patients.
b Other histologies: large cell undifferentiated, bronchoalveolar, squamous, and “other.”
EPP, expanded participation project; NSCLC, non-small cell lung cancer; NOS, not otherwise specified; PC, paclitaxel/carboplatin; PCB, paclitaxel/carboplatin  bevacizumab.
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subtype in E4599 (n  165), did not seem to show an OS
benefit, but did trend toward a nonsignificant PFS benefit
(HR  0.78, 95% CI: 0.55–1.09). Histologies in this study
were not centrally reviewed before categorization. Because
NOS encompasses a heterogeneous and poorly characterized
group of histologies,2 which may include squamous cell
elements, it would behoove physicians to obtain adequate
tissue specimen for more detailed analysis of NOS and other
histologies.
There were no new safety signals attributed to histology
that emerged from this analysis. The incidence of adverse
events associated with B therapy, such as grade 3 hyper-
tension, venous thromboembolic events, or proteinuria, was
higher in patients with adenocarcinoma who were treated
with PCB, but the distribution of these events was not
suggestive of a trend associated with histologic subtype.
Moreover, patients in the PCB group had a longer median
treatment time compared with the PC group, and only unad-
justed incidence rates were reported in this analysis. Because
of the limited numbers of patients with histology subtypes
other than adenocarcinoma and the low numbers of grade 3
or bevaciumab-targeted events involved (25 grade 3 bleed-
ing events reported in the entire population), small differ-
ences in event rates between treatment groups may not have
been detected.
The reasons for the selective survival advantage asso-
ciated with adenocarcinoma histology in this study remain
unclear. A histology analysis by Scagliotti et al10 from a
recent trial for patients who received cisplatin/pemetrexed,
compared with patients who received cisplatin/gemcitabine,
showed significant increased survival for patients with ade-
nocarcinoma or large-cell histology who received cisplatin/
TABLE 3. Adverse Events for Treated Patients, by Histologya
Adenocarcinoma Histology
(n  596)
NSCLC NOS Histology
(n  164)
Other Histologiesb
(n  108)
PCc (n  299) PCBd (n  297) PCc (n  86) PCBd (n  78) PCc (n  56) PCBd (n  52)
Any bleeding evente
Grade 3 2 (0.7) 4 (1.3) 0 1 (1.3) 0 2 (3.8)
Grade 4 0 4 (1.3) 0 0 0 1 (1.9)
Grade 5 3 (1.0) 4 (1.3) 0 3 (3.8) 0 1 (1.9)
Pulmonary hemorrhagef
Grade 3 1 (0.3) 2 (0.7) 0 0 0 0
Grade 4 0 1 (0.3) 0 0 0 0
Grade 5 1 (0.3) 2 (0.7) 0 3 (3.8) 0 1 (1.9)g
Hypertension
Grade 3 0 24 (8.1) 1 (1.2) 4 (5.1) 1 (1.8) 3 (5.8)
Grade 4 1 (0.3) 2 (0.7) 0 0 0 0
Arterial thromboembolic event
Grade 3 0 1 (0.3) 0 1 (1.3) 0 1 (1.9)
Grade 4 5 (1.7) 3 (1.0) 0 1 (1.3) 0 0
Grade 5 1 (0.3) 3 (1.0) 0 1 (1.3) 0 1 (1.9)
Venous thromboembolic events
Grade 3 5 (1.7) 8 (2.7) 2 (2.3) 0 0 1 (1.9)
Grade 4 5 (1.7) 12 (4.0) 2 (2.3) 2 (2.6) 0 0
Grade 5 0 1 (0.3) 0 0 0 0
Gastrointestinal perforation
Grade 3 1 (0.3) 4 (1.3) 0 2 (2.6) 1 (1.8) 0
Grade 4 0 3 (1.0) 0 0 0 1 (1.9)
Proteinuria
Grade 3 0 9 (3.0) 0 1 (1.3) 0 1 (1.9)
Grade 4 0 2 (0.7) 0 0 0 0
Neutropeniah
Grade 4 55 (18.4) 83 (27.9) 12 (14.0) 20 (25.6) 9 (16.1) 10 (19.2)
a Events were graded according to NCI-CTC, version 2.0. Events of maximum severity are reported for each patient. Rows for grade 5 events are only included for adverse events
categories that included grade 5 events.
b Other histologies include large cell undifferentiated, bronchoalveolar, squamous, and other.
c Source data are from the case report form.
d Source data are from the case report form and from the NCI Adverse Event Expedited Reporting System.
e Any grade 3 to 5 bleeding events, including pulmonary hemorrhage.
f Pulmonary hemorrhage events are a subset of bleeding events described in the row above. “Hemoptysis” was a preferred term for pulmonary hemorrhage events.
g This patient had large cell undifferentiated histology.
h Only grade 4 hematologic events are reported.
NSCLC, non-small cell lung cancer; NOS, not otherwise specified; PC, paclitaxel/carboplatin; PCB, paclitaxel/carboplatin  bevacizumab; NCI-CTC, National Cancer Institute
Common Terminology Criteria.
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pemetrexed. It was speculated that the more favorable OS for
adenocarcinoma was related to low thymidylate synthetase
expression in nonsquamous cells, associated with more ef-
fective pemetrexed activity in nonsquamous carcinomas.12,13
Thymidylate synthetase activity levels (in adenocarcinoma)
have not been shown to correlate with antivascular endothe-
lial growth factor activity. Any molecular or other mecha-
nisms that would explain the adenocarcinoma survival ad-
vantage in this study remain speculative and beyond the
scope of this assessment. The sample sizes of some histology
subgroups are not large enough for definitive treatment com-
parisons to be made between these subgroups.
Histologies documented in this study were per investi-
gator and were not centrally assessed. This may present a
limitation to this analysis and to other study analyses as well,
because prior studies have documented the difficulties and
inconsistencies with reporting of NOS histologies per inves-
tigator and central academic laboratory assessment, and there
is a degree of heterogeneity within the NOS subgroup it-
self.14,15 Patients with NSCLC of NOS histology have been
reported to have poorer survival and response to treatments,15
which may further confound this histology comparisons.
Although the results of this retrospective analysis rein-
force previous findings linking the inclusion of B in a com-
bination therapy regimen to improvements in OS and PFS,
conclusions are limited in the nonadenocarcinoma subtypes
primarily because of low patient numbers. An ongoing large,
observational cohort study is collecting histology and radio-
graphic data from approximately 2000 patients with different
NSCLC tumor histologies who are being treated with B in
combination with various chemotherapy regimens.16 This
study will permit further characterization of B treatment
outcomes in NSCLC as they relate to histologies.
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